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Abstract
Background: Housekeeping genes are commonly used as endogenous reference genes for the
relative quantification of target genes in gene expression studies. No conclusive systematic study
comparing the suitability of different candidate reference genes in clear cell renal cell carcinoma has
been published to date. To remedy this situation, 10 housekeeping genes for normalizing purposes
of RT-PCR measurements already recommended in various studies were examined with regard to
their usefulness as reference genes.
Results: The expression of the potential reference genes was examined in matched malignant and
non-malignant tissue specimens from 25 patients with clear cell renal cell carcinoma. Quality
assessment of isolated RNA performed with a 2100 Agilent Bioanalyzer showed a mean RNA
integrity number of 8.7 for all samples. The between-run variations related to the crossing points
of PCR reactions of a control material ranged from 0.17% to 0.38%. The expression of all genes did
not depend on age, sex, and tumour stage. Except the genes TATA box binding protein (TBP) and
peptidylprolyl isomerase A (PPIA), all genes showed significant differences in expression between
malignant and non-malignant pairs. The expression stability of the candidate reference genes was
additionally controlled using the software programs geNorm and NormFinder. TBP and PPIA were
validated as suitable reference genes by normalizing the target gene ADAM9 using these two most
stably expressed genes in comparison with up- and down-regulated housekeeping genes of the
panel.
Conclusion: Our study demonstrated the suitability of the two housekeeping genes PPIA and TBP
as endogenous reference genes when comparing malignant tissue samples with adjacent normal
tissue samples from clear cell renal cell carcinoma. Both genes are recommended as reference
genes for relative gene quantification in gene profiling studies either as single gene or preferably in
combination.
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Background
Gene expression studies in tumour tissue in comparison
with its corresponding normal tissue counterpart open up
prospects for identifying new biomarkers and targets char-
acteristic of the respective tumour entity. For that purpose,
the relative quantification of reverse transcription-PCR
(RT-PCR) data is the method of choice to ascertain gene
expression results [1,2]. This method is based on the nor-
malization of the target gene expression on any stably
expressed internal reference gene, a so-called "housekeep-
ing" gene, measured in the same biological material. A
crucial problem involved here is finding such a suitable
reference gene which has to be tested and verified under
defined study conditions. The general conditions a refer-
ence gene must meet is that its expression in the samples
studied be stable, non-regulated and constant and not be
influenced by biological (e.g., age, gender, metabolism,
disease stage) or experimental (e.g., addition or depriva-
tion of physiological, physical or chemical agents) condi-
tions or treatments [3-6]. In addition, the reference gene
and the target gene should have similar ranges of expres-
sion to avoid analytical problems.
In literature, several single housekeeping genes or house-
keeping gene indexes summarizing two or more house-
keeping genes have been used for relative quantification
[4,5,7,8]. However, these genes were often adopted with-
out exact knowledge of their individual expression behav-
iour under the special study conditions. Recently, we
discussed that issue in two studies concerning the identi-
fication of candidate reference genes for the relative quan-
tification of expression data in the urological tumours of
the prostate and bladder [8,9].
Renal cell carcinoma (RCC) is another important urolog-
ical tumour. In 2007, RCC is estimated to cause 51.190
new cases and 12.890 deaths in the USA [10]. RCC is, in
most cases, clinically asymptomatic and casually detected
by routine ultrasonographic follow-ups in persons other-
wise in generally good health [11]. The clear cell subtype
of RCC (ccRCC) is the most frequent malignant RCC
showing an incidence of about 75% [12]. It has a worse
prognosis in comparison with the papillary and chromo-
phobe RCC subtypes that account for 10% and 5% of
RCC, respectively [12]. Although numerous tumour
markers in RCC were tested in the past, to date no defini-
tive biomarkers are available for diagnosis, monitoring,
and predicting the outcome of RCC [13]. Thus, there is an
urgent need to search for new markers. To identify poten-
tial new candidates gene expression profiles using the
DNA microarray technique and subsequent RT-PCR
assays are helpful tools [14]. Therefore, we searched for
suitable normalization genes for gene expression studies
on RCC tissue samples. Our strategy was the same as that
used in studies of prostate and bladder normalization
gene findings [8,9]. Using the MeSH terms "renal cell car-
cinoma", "gene expression", and "RT-PCR" combined
with the Boolean operator "AND" we performed a
PubMed search of articles published from October 1993
to August 2006. We had access to 156 articles that used 19
various reference genes (Table 1). It was remarkable that
beta-actin (ACTB; 64 times; 37%) and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH; 63 times; 36%) were
used as normalizer genes in about three quarters of all
studies. The use of these two genes for normalization is
historically grown. Although their regulated expression
shown under different conditions is inconsistent with
their use as normalizers [1,15], this fact has often been
disregarded till now or at least it has not been checked
under the study conditions [15-18]. All other housekeep-
ing genes cited accounted for only 1 to 6%. Only a few
studies compared or used more than one reference gene,
often in other organisms [19-21] or under other clinical
conditions [7,22,23]. This literature search clearly proves
that an univocal reference gene for gene expression studies
in renal cell carcinoma does not exist. The search results
additionally emphasize the need for a systematic study to
identify suitable reference genes for gene expression stud-
ies in renal cell carcinoma.
The aim of this study was to identify suitable reference
genes for the purpose of normalization in RCC gene
expression studies. Therefore, we examined a panel of 10
candidate reference genes listed in Table 2 with regard to
their expression behaviour in 25 matched malignant and
non-malignant RCC tissue samples. This investigation
was focused on the clear cell RCC subtype as the most fre-
quent malignant RCC. We selected as potential reference
genes either genes taken from the above-mentioned liter-
ature search or genes that were shown to be appropriate
for normalization in previous studies of other tissues
[6,8,9]. The suitability as reference gene was estimated by
comparing the expression stability of the respective gene
in malignant and non-malignant tissue using different
mathematical procedures and computer programs. The
use of unsuitable reference genes in the normalization
procedure could result in serious errors in gene expression
studies, which could lead to wrong conclusions being
drawn [8,24-26]. These aspects are illustrated by the
example of the relative gene quantification of "a disin-
tegrin and metalloproteinase domain 9" (ADAM9) using
up- and down-regulated housekeeping genes as normaliz-
ers.
Results
Assessment of preanalytical and analytical variables
Preanalytical variables like the collection and storage of
samples and the process of RNA isolation determine the
quality of RNA that is used for subsequent quantitative
expression analyses. RNA quality, as a summary parame-BMC Molecular Biology 2007, 8:47 http://www.biomedcentral.com/1471-2199/8/47
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ter, characterizes possible negative effects with regard to
deficient procedures of collection and preparation of tis-
sue samples. Therefore, the isolated RNA samples from
the 25 matched malignant and non-malignant samples
were characterized with regard to their concentration,
purity, and integrity. Only RNA samples with high quality
should be included in this study to avoid erroneous con-
clusions. However, all RNA samples isolated from renal
tissue specimens preserved in RNAlater solution exhibited
a high quality. The mean A260/280 ratio of RNA samples
was 2.05 ± 0.027 (range from 1.99 to 2.12.) and reflected
pure and protein-free RNA. The RNA integrity as an essen-
tial quality criterion was characterized by the so-called
RNA integrity number (RIN) measured on the Agilent
2100 Bioanalyzer. The mean RIN value (± SD) of all RNA
samples was 8.7 ± 0.77 (range from 7.0 to 10.0). The
matched malignant and non-malignant tissue samples
reached mean RIN values (and SD) of 9.09 ± 0.57 and
8.32 ± 0.75, respectively, whose difference was significant
(paired Student's t test; P < 0.001). Preceding orienting
comparisons of RIN values measured in RNA samples iso-
lated from paired tissue specimens stored in RNAlater
solution or snap-frozen in liquid nitrogen immediately
after surgery showed significantly higher values obtained
using the former manner of preservation (n = 10; mean
RIN value and SD of 8.21 ± 1.02 vs. 5.42 ± 2.80; P <
0.004). We therefore exclusively used RNAlater solution
for tissue preservation.
There was a strong correlation between the RIN values of
the paired samples (rs = 0.635, P < 0.001). All gene expres-
sion levels both in the malignant and non-malignant
samples did not correlate with the RIN number (rs = -
0.012 to 0.325; P = 0.956 to 0.113) as it was shown as
proof for intact, high quality RNA [27].
Pooled cDNA samples were used as precision control
materials for each gene-specific PCR run. These control
materials were adjusted to the ranges of Cp values that
were characteristic for the particular genes in the tissue
samples. Intra-run and between-run analytical perform-
ances of the RT-PCR measurements were determined
using these control materials. The intra-run precision (n =
12) was 0.26% and 3.56% for ACTB amplifications with a
mean Cp-value of 21.26 and the corresponding mean
concentration of 4.59 arbitrary units, respectively. The
between-run variations (n = 5) ranged from 0.17% (Cp
mean 25.63 ± 0.04 of SDHA control cDNA) as the lowest
to 0.38% (Cp mean 26.46 ± 0.10 of HMBS control cDNA)
as the highest value. Corresponding coefficients of varia-
tion for the concentrations data ranged from 2.26% to
10.9%.
Expression levels of candidate reference genes
Paired malignant and non-malignant samples were
always measured in the same analytical run to exclude
between-run variations. Expression levels of the 10 inves-
Table 1: Reference genes used for gene expression studies in renal cell carcinoma
Gene name Publications using that gene as reference gene
Number %
GAPDH 63 36.4
ACTB 64 37.0
18S ribosomal RNA 10 5.8
Beta-2-microglobulin 7 4.0
RPLPO 52 . 9
HMBS 31 . 7
HPRT1 31 . 7
PPIA 31 . 7
TBP 31 . 7
Alpha tubulin 3 1.7
ALAS1 10 . 6
Enolase 1, (alpha) 1 0.6
Beta globin 1 0.6
Karyopherin alpha 6 1 0.6
Membrane cofactor protein 1 0.6
Phosphoglycerate kinase 1 1 0.6
Ribosomal protein L7 1 0.6
Ribosomal protein S9 1 0.6
Ribosomal protein S14 1 0.6
Results of a PubMed search from October 1993 to August 2006 with 156 articles and 173 descriptions of different reference genes. Candidate 
reference genes tested in the present study are given as gene symbols in bold letters and their corresponding full names and accession numbers are 
indicated in Table 2. Further comments concerning the search results see the section "Limitations of this study".BMC Molecular Biology 2007, 8:47 http://www.biomedcentral.com/1471-2199/8/47
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tigated candidate reference genes (Table 2) shown in
terms of Cp-values are given as box-and-whisker-plots in
Figure 1. Twenty-five matched samples were included in
this study. The boxes represent the median Cp-values and
interquartile ranges, the whiskers indicate the 10–90 per-
centile ranges. Since the expressions measured in the two
sample groups were not always normally distributed
(D'Agostino & Pearson omnibus normality test), the non-
parametric Wilcoxon signed rank test was applied for all
significance calculations. Genes with higher expression
levels show a lower Cp-value under the specific PCR con-
ditions and lower expressed genes have reversely higher
cycle numbers. The Cp-values of all measured genes were
between 19 and 31. The genes ACTB,  GAPDH,  PPIA,
RPLPO,  SDHA, and TUBB  achieved mean Cp-values
between 20 and 25 cycles while the lower expressed genes
ALAS1,  HMBS, HPRT1, and TBP  achieved Cp-values
between 25 and 29 cycles. As shown in the Figure 1, all
genes except PPIA and TBP showed significantly different
Cp-values between the malignant and non-malignant
samples. PPIA was the highest expressed gene with mean
(± SD) Cp-values of 20.04 ± 0.97 in non-malignant and
20.04 ± 0.75 in malignant samples. The TBP gene was the
lowest expressed gene with mean (± SD) Cp-values of
29.55 ± 0.53 in non-malignant and 29.72 ± 0.67 in malig-
nant samples.
Significance calculations between gene expression data of
paired malignant and non-malignant samples were per-
formed on the basis of concentrations instead of Cp-val-
ues, taking into account the different PCR efficiencies as
indicated in Table 2. To facilitate the survey of the results,
the differential expression of all 10 genes investigated is
separately shown for all matched samples (Figure 2a–k).
Non-regulated (Figure 2a–c), up-regulated (Figure 2d–g),
and down-regulated (Figure 2h–k) genes were grouped.
Significantly different gene expressions between malig-
nant and non-malignant samples were observed for all
genes with the exception of the genes PPIA (P = 0.605)
and TBP  (P = 0.371) (Figure 2a–c). Since the smallest
mean Cp difference is 0.4 and since retrospective power
calculations have yielded a high power (approx. 85%), a
type II error can be ruled out with a high probability. The
expressions of ACTB (P = 0.0132), GAPDH (P = 0.0002),
TUBB (P = 0.0002), and RPLPO (P = 0.0007) were signif-
icantly increased in malignant compared with the
matched non-malignant samples (Figure 2d–g). In con-
trast, the levels for ALAS1  (P < 0.0001), HPRT1  (P <
Table 2: Characteristics of gene-specific real-time PCR assays
Gene symbol Gene name Accession No. Primer/Probe Sequence [5'→3'] Amplicon Size [bp] Detection Dye/Probe PCR Efficiencyd
ACTB Actin, beta NM_001101 Forward: agcctcgcctttgccga
Reverse: ctggtgcctggggcg
Probe: F-ccgccgcccgtccacacccgccT-P
174 TMa 1.89
ALAS1 5-Aminolevulinate delta-, 
synthase 1
NM_000688 LightCycler-h-ALAS
Housekeeping Gene Set
Roche (Cat. No. 03 302 504 001)
127 Hybb 1.97
GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase
NM_002046 Forward: gaaggtgaaggtcggagtc
Reverse: gaagatggtgatgggatttc
Probe: F-caagcttcccgttctcagccT-P
226 TM 1.99
HMBS Hydroxymethyl-bilane synthase 
Alias: Porphobilinogen 
deaminase (PBGD)
NM_000190 LightCycler-h-PBGD
Housekeeping Gene Set
Roche, Cat. No. 03 146 073 001
150 Hyb 1.98
HPRT1 Hypoxanthine phosphoribosyl 
transferase 1
NM_000194 LightCycler-h-HPRT
Housekeeping Gene Set
Roche (Cat. No. 03 261 891 001)
181 Hyb 2.00
PPIA Peptidylprolyl isomerase A
Alias: Cyclophilin A
NM_021130 Hs_PPIA_1_SG QuantiTect Primer 
Assay
Qiagen (Cat. No. QT00052311)
121 SGIc 1.84
RPLPO Ribosomal protein, large, PO NM_001002 Hs_RPLPO_1_SG QuantiTect Primer 
Assay
Qiagen (Cat. No. QT00075012)
79 SGI 1.92
SDHA Succinate dehydrogenase 
complex,
subunit A, flavoprotein (Fp)
NM_004168 Forward: cactggaggaagcacaccc
Reverse: ccttcccagtgccaacgtccacaat
Probe: F-ccttcccagtgccaacgtccacaaT-P
78 TM 1.92
TBP TATA box binding protein NM_003194 Forward: ttcggagagttctgggattgta
Reverse: tggactgttcttcactcttggc
Probe: F-ccgtggttcgtggctctcttatcctcaT-P
227 TM 1.88
TUBB Tubulin, beta NM_178014 Hs_TUBB_1_SG QuantiTect Primer 
Assay
Qiagen (Cat. No. QT00089775)
120 SGI 1.98
ADAM9 ADAM metallopeptidase 
domain 9,
(meltrin gamma)
NM_003816 Forward: ggtgacagatttggcaattgtg
Reverse: ttgtgccttcgttaaccatcc
Donor probe:
acgcctagtcgaggcaccaaatgttg-6Fl
Acceptor probe:
Cy5.5-gtgtggatttccagctaggatcagatgttcc-P
226 Hyb 1.95
aTM = TaqMan probes are 3'-end F, FAM (6-carboxy-fluorescein) and near 5'-end T, TAMRA (6-carboxy-tetramethyl-rhodamine) labelled and P, phosphorylated
bHyb = Hybridization probes, two different labelled probes are included in the kit (Roche); for target gene see text
cSGI = SYBR® Green I fluorescent dye
dPCR efficiencies were calculated according to Rasmussen [2].BMC Molecular Biology 2007, 8:47 http://www.biomedcentral.com/1471-2199/8/47
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0.0001), HMBS (P = 0.0002), and SDHA (P = 0.0043)
were significantly decreased in malignant tissue parts (Fig-
ure 2h–k). Thus, a statistical type I error for these eight
genes is very unlikely because of the low P values. In con-
sequence, only the two genes PPIA  and  TBP  fulfil the
essential criterion of a reference gene for gene profiling
studies in renal cell carcinoma.
Except for TUBB and GAPDH the expression rates of the
genes significantly correlated between the malignant and
non-malignant samples (rs of 0.429 to 0.790; P = 0.032 to
P < 0.0001). The expression of all genes in malignant and
non-malignant samples did not depend on age (rs = -
0.001 to 0.282; P = 0.996 to 0.172), sex (Mann-Whitney
test; P = 0.096 to 1.00), and tumour stage (Mann-Whitney
test of pT1+2 vs., pT3 or pT1 vs. pT2+3, and pT1 vs. pT3;
P = 0.104 to 0.976). The effect of grading could not be
estimated, since 23 of the 25 malignant samples were
grade 2 and only one had grades 1 and 3.
Expression stability testing of candidate reference genes
PPIA and TBP as the two suitable reference genes were
included in the software program geNorm [4,28] to calcu-
late a common normalization factor using the data of
these two genes. The application of the normalization fac-
tor of these two genes is shown in Figure 2c; it yielded
comparable data if only one of the two reference genes
PPIA or TBP was used for normalization. We also included
all 10 candidate reference genes in the program geNorm
to calculate the average expression stability value M for all
genes without excluding the genes differently expressed in
the matched pairs. The ranking order from the most
unstable to the most stable genes was as follows: TUBB,
RPLPO, GAPDH, ACTB, SDHA, PPIA, TBP, HMBS, ALAS1,
and  HPRT1. The last remaining two genes ALAS1  and
HPRT1 achieved a stability value of 0.426 as the most sta-
ble genes. It is remarkable that all genes had average
expression stability M values less than 1.5 that is defined
in the program as stability cutoff value. However, these
results show that the program was not able to identify the
genes with significant expression differences between
malignant and non-malignant sample pairs.
Using the NormFinder program [29,30] as another free
tool available on the internet to validate the expression
stability of the candidate reference genes, the two genes
PPIA and TBP also achieved the best stability values (Table
3). With the aid of this program, PPIA was identified as
the most stable single gene with a stability value of 0.074.
Thus, the stability data calculated with that program as a
combined estimate of intra- and intergroup expression
variations of the genes studied reflect to a certain extent
the expression differences of the genes observed in the
matched pairs.
Expression levels of target gene influenced by 
normalization genes
The expression levels of the target gene ADAM9 is used
here as an example to demonstrate the effect of different
normalization genes on the relative gene expression data.
We determined the ADAM9 mRNA expression in the same
25 RNA sample pairs as used for the reference gene search.
The ADAM9 expressions were normalized using different
strategies (Figure 3). ADAM9  expression values were
related either to the single non-regulated reference genes
PPIA and TBP, the mean ratio of both genes (mr), the nor-
malization factor (NF) obtained for these two genes using
the program geNorm, or to the three up-regulated genes
GAPDH, ACTB, and TUBB as well as to the two down-reg-
ulated genes ALAS1 and HPRT1. To better compare the
effect of these different normalization approaches, the rel-
ative ADAM9 mRNA expression in non-malignant sam-
ples was set 1.0 and expression rates in the matched
malignant samples were calculated as multiples (Figure
3). A significant up-regulation of ADAM9 mRNA in malig-
nant tissue samples was proved when the normalization
approach was performed either with the two stable refer-
ence genes PPIA and TBP or with the mean ratios of both
genes and the normalization factor calculated for the two
genes using the geNorm program. In contrast, the normal-
ization of ADAM9 expression data on the up-regulated
genes resulted in a partly decreased ADAM9  mRNA
Expression levels of candidate reference genes in non-malig- nant and malignant renal cell carcinoma samples Figure 1
Expression levels of candidate reference genes in 
non-malignant and malignant renal cell carcinoma 
samples. Values are given as real-time PCR crossing points 
(Cp) cycle numbers. Boxes (blank: non-malignant; cross stri-
ated: malignant) represent the lower and upper quartiles 
with medians; whiskers illustrate the 10 to 90 percentiles of 
the samples. All Cp values except PPIA (P = 0.339) and TBP (P 
= 0.257) significantly differed between non-malignant and 
malignant samples (P of 0.0089 to < 0.0001; Wilcoxon test).BMC Molecular Biology 2007, 8:47 http://www.biomedcentral.com/1471-2199/8/47
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Differential mRNA expression of candidate reference genes in matched non-malignant (N; blank circles) and malignant renal  cell carcinoma (ccRCC; black circles) tissue samples shown as connected lines Figure 2
Differential mRNA expression of candidate reference genes in matched non-malignant (N; blank circles) and 
malignant renal cell carcinoma (ccRCC; black circles) tissue samples shown as connected lines. (a-c). Gene 
expression of non-regulated reference genes PPIA and TBP. The Normalization Factor was calculated from both non-regulated 
genes with the program geNorm (see text). (d-g). Gene expression of up-regulated candidate reference genes GAPDH, ACTB, 
TUBB, and RPLPO. (h-k). Gene expression of down-regulated candidate reference genes HPRT1, ALAS1, HMBS, and SDHA. Sig-
nificances were calculated with the Wilcoxon test of paired samples.
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expression, whereas the normalization procedure with the
down-regulated genes resulted in an about three-fold
enhancement of the up-regulation of ADAM9  mRNA
expression in malignant tissue samples.
Discussion
The essential result of our study evaluating 10 candidate
reference genes for normalizing gene expressions of clear
cell RCC was that only the two genes PPIA and TBP did
not differ in their expression in malignant and in non-
malignant tissue pairs. Consequently, only these two
genes fulfil the criterion of expression stability between
matched tissue samples and could be recommended as
accurate normalizers for relative gene quantification in
clear cell RCC samples. In the following, this conclusion
and data will be discussed, taking into account four main
aspects of the current study: (a) the particular study con-
ditions concerning the preanalytical and analytical varia-
bles, (b) the panel of the candidate reference genes
studied, (c) the validation of suitable reference genes, and
(d) the limitations of the study.
Preanalytical and analytical study conditions
Like in our previous experiments with reference genes
[8,9], the preanalytical and analytical design of our study
is defined by three characteristics: 1) use of paired malig-
nant and non-malignant tissue samples from the same
nephrectomized organ; 2) use of high-quality RNA sam-
ples as precondition for reliable RT-PCR measurements;
3) high analytical performance realized by measurements
on the LightCycler. We consider these preconditions
essential to achieve a suitable normalization for gene
expression studies. Recently, Huggett et al. [17] recom-
mended a similar approach.
The use of paired samples from the same RCC instead of
unpaired samples for comparative gene expression studies
has the particular advantage of minimizing the interindi-
vidual variation effect and increasing the statistical signif-
icance of the study [8,9]. The correlations between the
corresponding gene expressions in the malignant and
non-malignant tissue samples support the view that inter-
individual expression variations do occur. In conse-
quence, differential gene expressions can be easier
ascertained so that the use of paired samples results in a
more exact validation regarding the suitability of reference
genes than a study using unpaired samples. Therefore, the
use of paired samples is the method of choice in identify-
ing suitable reference genes for differential gene studies
between malignant and non-malignant samples. In clini-
cal research the detection of different gene expression lev-
els between non-malignant and malignant tissues is an
important objective. The results are starting points for fur-
ther studies on translational stage with the final goal of
developing new diagnostic markers or therapeutic
approaches. However, in validating of suitable reference
genes, one should above all, consider that the expression
of candidate reference genes can be influenced by physio-
logical factors like age, sex, pathological factors like the
tumour characteristics stage and grade or other biological
conditions [23,29,31-34]. The results of our data proved
that the expression of all genes was not dependent on age,
sex, and tumour stage.
Another characteristic of our study was the use of high-
quality RNA samples as an important prerequisite to
obtain reliable RT-PCR results [17,35] for selecting stable
reference genes. For expression measurements, we used
only RNA samples with an A260/A280 ratio > 1.95 and RIN
values > 7.0, as an index of high purity and integrity of the
RNA samples. We controlled the quality of each RNA sam-
ple with the Agilent 2100 Bioanalyzer. The principle of
the bioanalyzer technology is based on microcapillary
electrophoresis [27,36]. Electropherograms and gel-like
images can be visually evaluated and an expert software
can generate an RNA integrity number (RIN). The RIN
algorithm evaluates six regions of the electropherogram in
addition to the conventional ratio of 28S rRNA to 18S
rRNA [27,36]. The RIN allowed a user-independent
assessment of RNA integrity. Although mRNA only
accounts for 2–5% of total RNA, the RIN value provides a
relevant information concerning downstream applica-
tions [35]. Based on the correlation analysis of RIN values
to RT-PCR data, Schroeder et al. [27] defined for their
experiments a RIN value of 6 as a threshold for high and
low RNA quality while the low quality RNA was consid-
ered unacceptable for downstream measurements. Collec-
tion, storage, and processing of the tissue samples are the
essential preanalytical variables that affect the RNA integ-
rity as a global indicator of all detrimental processes
occurring during the time between the collection of sam-
ples after surgery and isolation of RNA [27,37]. The iso-
lated high-quality RNA in our experiments and the proof
of the non-correlation of RIN values with the expression
results confirmed that possible distorting effects by non-
intact RNA could be avoided. In addition, the use of RNA
samples with similar degrees of integrity is shown in our
experiments by the strong correlation of the paired RNA
samples (rs = 0.635, P < 0.001). There was a mean RIN dif-
ference of only about 0.7 that minimized the variability of
the RNA content in the cDNA synthesis followed by more
stable quantitative RT-PCR data. In fact, Auer et al. [38]
suggested that samples of comparable RNA intactness
could be used for microarray analysis despite a certain
degradation. Our previous experiments have shown that
not only the interval time between the removal of the
organ and preservation, but also the method of preserva-
tion is decisive for the integrity of RNA. Comparisons of
RIN values measured in RNA isolated from paired tissue
samples stored in RNAlater solution or snap-frozen in liq-BMC Molecular Biology 2007, 8:47 http://www.biomedcentral.com/1471-2199/8/47
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uid nitrogen immediately after surgery showed signifi-
cantly higher values using RNAlater-preservation.
Therefore, we consider the use of RNAlater solution as
method of choice in preservating renal tissue for obtain-
ing intact RNA for reliable expression results. RNAlater
was also recently recommended for preserving RNA integ-
rity in routine clinical kidney biopsy material [39].
The analytical performance of the RT-PCR measurements
was characterized by low variation coefficients of Cp-val-
ues ranging from 0.17 to 0.38% in between-run precision
experiments. This high analytical precision, together with
the use of paired samples and their measurement in the
same analytical run, enabled us to carry out data analysis
with high statistical probability.
Panel of the candidate reference genes studied
As briefly outlined in the Introduction, a systematic study
concerning the suitability of reference genes for normali-
zation in RCC expression studies has been lacking so far.
Schmid et al. [7] performed a Medline search about refer-
ence genes used in renal tissue in general. Although, as
reported, we included in our PubMed search only publi-
cations concerning RCC (Table 1), we, like Schmidt et al.
[7], found GAPDH and ACTB to be the most frequently
used genes for normalization. It should be mentioned
that the search strategy in PubMed using the MESH terms
"renal cell carcinoma" in conjunction with the terms "RT-
PCR" and "gene expression" was limited, since published
studies not indexed with these terms cannot be found. The
reviewer drew our attention to this point after our study
was finished. For example, the study by Janssens et al. [40]
using the gene mitochondrial ATP synthase 6 (mATPsy6)
in addition to GAPDH and HMBS (named by the authors
as PBGD) as reference genes in various cell lines and tis-
sues was not found with this strategy and was not
included in this study. However, we believe that despite
this limitation, the overview in Table 1 served as good
starting point for our study. The selection of eight out of
the 10 candidate reference genes in our study resulted
from this search to facilitate comparison, while the two
additional genes TUBB and SDHA were included into the
panel of candidate reference genes due to their utility
shown in other studies [6,8,9]. All these candidate refer-
ence genes studied are widely used in other studies. Our
study was performed to search for stable housekeeping
genes in a large panel of candidate reference genes cover-
ing a broad expression range. The two genes 18S-ribos-
omal RNA and beta-2-microglobulin also commonly
applied as normalizers in RCC samples (Table 1) were not
included in our study panel because they belong to the
highly expressed and regulated genes in renal tissue [6].
Moreover, the use of 18S-ribosomal RNA as reference
gene would be only possible if random primed reverse
transcription was carried out for cDNA synthesis.
Validation of the suitable reference genes
To identify the suitable reference genes as normalizers in
gene expression studies, several strategies including com-
puter programs have been recommended [1,17,23,29,40-
43]. There is no doubt that the absence of the differential
expression of the candidate reference gene examined in
the study groups in question or under conditions to be
compared is the strongest proof of suitability. Therefore,
we proposed to use a two-step strategy for identifying suit-
able reference genes according to our study design of
matched malignant and non-malignant samples [8,9].
First, the expression of the candidate reference genes
between the respective study groups or conditions is com-
pared using the appropriate paired tests. It can be assumed
that genes with significantly different expressions are not
suited to target gene normalization, since they are affected
by the study condition in question. Those genes should be
excluded as normalizers. In the current study, the expres-
Table 3: Candidate reference genes for normalization and their expression stability values calculated by NormFinder
Ranking order Gene Stability value
1 PPIA 0.074
2 TBP 0.123
3 ACTB 0.199
4 HMBS 0.301
5 SDHA 0.308
6 HPRT1 0.402
7 GAPDH 0.436
8 RPLPO 0.453
9 ALAS1 0.481
10 TUBB 0.514
A low stability value as an estimate of the combined intra- and intergroup variation of the respective gene corresponds to a high expression stability 
of the respective gene between the matched malignant and non-malignant samples.BMC Molecular Biology 2007, 8:47 http://www.biomedcentral.com/1471-2199/8/47
Page 9 of 13
(page number not for citation purposes)
sion of all genes except that of PPIA and TBP varied in the
matched malignant and non-malignant samples. The dif-
ference in expression was observed not only in the two
genes ACTB and GAPDH, which are most frequently used
as normalizers in RCC studies, but also in the gene
HPRT1. The latter was recently recommended as single
reference gene for gene expression studies in cancer
research [44]. It was also identified as a suitable reference
gene in RCC samples by Haller et al. [23] using the equiv-
alence test. However, this discrepancy to our results might
be due to the fact that Haller et al. [23] only studied 10
paired samples with an obviously lower statistical power
compared with that in our experiments with 25 paired
samples.
In the second step of our approach, we generally calcu-
lated the best-performing reference genes using the
geNorm and NormFinder programs [8,9]. Whereas in
prostate cancer and bladder cancer experiments 13 out of
16 and six out of nine genes, respectively, remained as
suitable genes for the further calculations with geNorm
and NormFinder [8,9], only the two genes PPIA and TBP
could be considered for these analyses in the current
study. It is worth mentioning that the geNorm program
ADAM9 mRNA expression in malignant tissue samples compared to non-malignant paired samples in depending on different  normalization approaches Figure 3
ADAM9 mRNA expression in malignant tissue samples compared to non-malignant paired samples in depend-
ing on different normalization approaches. Gene expression in the matched malignant tissue samples was calculated as 
multiple of the expression in the non-malignant sample that was set 1.0. The columns represent the median and interquartile 
ranges of the multiple gene expression. The four blank columns result from ADAM9 mRNA expression related to the two non-
regulated reference genes (PPIA, TBP) and to the normalization factors (mr, of the two genes; NF, calculated using geNorm; see 
text). The three striped and two black columns illustrate the normalization of ADAM9 expression using either up-regulated 
(GAPDH, ACTB, and TUBB) or down-regulated (ALAS1 and HPRT1) genes.
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was unable to detect candidate reference genes that were
characterized as unsuitable reference genes in the first step
of suitability testing. In contrast, NormFinder recognized
PPIA and TBP as the two best-performing reference genes
when all candidate reference genes were included for the
calculation (Table 3).
A target gene normalization was used as an example to
illustrate the validation of a suitable reference gene
selected from a panel of candidate reference genes. We
used "a disintegrin and metalloproteinase domain 9"
(ADAM9) as the target gene. Without going into details
about the possible significance of ADAM9  in RCC
tumourigenesis, we can say that the various relative quan-
tification methods shown here can result in serious gene
quantification errors if unsuitable reference genes are used
(Figure 3). We recommend the use of PPIA and TBP for
normalizing expression results using the mean ratio of rel-
ative quantification with the two reference genes.
Although the advantage of using both reference genes for
normalizing is not clearly evident in our study, other
authors showed a more accurate normalization when
more than one reference gene was used [4,7,33].
Limitations of this study
Some limitations of this study should be mentioned. The
first limitation could be seen in the limited number of
samples used in the current study. In contrast to this lim-
itation, it is remarkable that even with the possibly low
statistical power due to the limited number of samples,
clearly significant results of eight candidate reference
genes were obtained. Thus, as explained in the previous
section, the risk of a type II error and also of a type I error
is rather unlikely as the problem with small studies does
not exist in our study. Second, the present study is limited
to the clear cell RCC subtype. However, that type is the
most frequent malignant RCC. The expression of the two
recommended reference genes PPIA and TBP in the papil-
lary or chromophobe RCC subtypes was not studied and
it would be necessary to confirm their potential use in fur-
ther studies. Third, the study was partly unbalanced with
regard to sex, tumour stage, and grade. The study included
21 males, but only 4 females. However, since there were
no differences for all genes studied, we can assume,
despite this unbalanced design, that the expression did
not depend on sex. Similarly, the tumour stage obviously
did not influence the expression level as shown in the
Results. Twenty-three out of 25 samples had the tumour
grade 2. Whereas it can be assumed that at least PPIA and
TBP are suitable reference genes for grade 1, their useful-
ness as normalizer in grade 3 RCC samples remains to be
verified. Fourth, although we examined the most compre-
hensive panel of potential housekeeping genes in compar-
ison with other studies, we measured only 10 genes,
excluding genes very rarely used for renal cell carcinoma
due to the limited sample material available (Table 1).
Thus, the question remains unanswered whether these or
other genes including the mitochondrial ATP synthase 6
gene mentioned above are equivalent to or more suitable
than the recommended genes PPIA and TBP.
Conclusion
The two housekeeping genes PPIA and TBP are the sole
stably expressed genes from a panel of 10 candidate refer-
ence genes studied in matched malignant and non-malig-
nant tissue samples from the clear cell RCC. Both genes
are recommended as reference genes for relative gene
quantification in gene profiling studies either as single
gene or preferably in combination.
Methods
Patients and samples
Kidney tissue samples derived from 25 adult patients with
RCC (21 male, four female, mean age 62 years, range: 45
to 92 years) undergoing radical nephrectomy at the
Department of Urology of the University Hospital Charité
between September 2003 and January 2006. The use of
the tissue material for research was approved by the Med-
ical Ethical Committee of the Charité Hospital (Chair-
man: Prof. R. Uebelhack, University Hospital Charité,
Berlin, Germany; protocol "Detection of metalloprotein-
ases in patients with genitourinary cancer"; July 16,
2002). Matched malignant and non-malignant specimens
from the same kidney were collected immediately after
surgery in tubes with RNAlater®  Stabilization Reagent
(Qiagen, Hilden, Germany), stored at 4°C overnight, and
then put in long-time storage at -80°C until RNA isola-
tion.
Tumour stage and classification were established accord-
ing to the 2002 TNM System and the 2004 WHO Classifi-
cation [12,45]. All tumours were clear cell carcinoma
(ccRCC). Eleven of the 25 tumours studied were classified
stage pT1, two tumours pT2, and 12 tumours pT3. The
histological grading was once G1, 23 times G2, and once
G3. None of the patients had metastases (M0 and pN0).
RNA isolation and characterization
Total RNA was isolated from about 50 mg of preserved
kidney tissue samples cut into small pieces and homoge-
nized in 350 μl RNA lysis/binding buffer including 1%
beta-mercaptoethanol. The RNeasy Mini Kit (Qiagen) was
used for RNA isolation according to the manufacturer's
instructions. An additional digestion step on the RNA
binding silica gel membrane of the spin column was per-
formed with DNase I. The RNA yield and the ratio of
absorbance at 260 nm to 280 nm (A260/A280 ratio) were
measured with the NanoDrop®ND-1000 Spectrophotom-
eter (NanoDrop Technologies, Montchanin, DE, USA).BMC Molecular Biology 2007, 8:47 http://www.biomedcentral.com/1471-2199/8/47
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The integrity of isolated total RNA was assessed with the
RNA 6000 Nano LabChip® kit using the Agilent 2100 Bio-
analyzer (Agilent Technologies, Palo Alto, CA, USA). Agi-
lent 2100 Expert software was used to generate a so-called
RNA Integrity Number (RIN) as criterion of the RNA qual-
ity for downstream experiments. The RIN values are scaled
from number 1 (RNA completely degraded) to 10 (intact
RNA) [27,35,36].
First strand cDNA synthesis
One μg RNA was reversely transcribed using the Transcrip-
tor First Strand cDNA Synthesis Kit (Roche Applied Sci-
ence, Penzberg, Germany) with random hexamer priming
method according to the manufacturer's recommenda-
tions. This kit was selected as result of previous compara-
tive studies between various cDNA synthesis kits. That kit
offers a fast, complete, and high-yield cDNA synthesis
[46]. Briefly, RNA samples and random primers were
mixed and denatured for 10 min at 65°C. Thereafter,
tubes were immediately placed on ice. The first strand
cDNA synthesis was started after adding transcription
mixture at 25°C for 10 min (random primer annealing)
following 30 min at 55°C for reverse transcriptase reac-
tion. Finally, the enzymes were inactivated at 85°C for 5
min. Each RNA sample was controlled for genomic con-
tamination without reverse transcriptase addition into
cDNA synthesis mixture. cDNA samples were stored at -
20°C and diluted 1:5 with RNase-free water for use as
template in real-time PCR analysis.
Real-time RT-PCR
Real-time PCR was performed with the LightCycler instru-
ment (Roche) by using different measurement and detec-
tion modes. The primer and probe sequences applied for
the cDNA amplification of the ten candidate reference
genes and one target gene are given in Table 2. The
primer/probes sequences and PCR run conditions for the
detection of ACTB, ALAS1, GAPDH, HMBS, HPRT1, SDH,
and TBP were used as previously described [9]. For PPIA,
RPLPO, and TUBB, real-time PCR pre-designed assays
(Qiagen) based on detection with SYBR Green I (SGI) flu-
orescence dye were used. cDNA amplification for these
three genes were performed with the QuantiTect SYBR
Green Master Mix (Qiagen) that contained HotStar Taq
DNA polymerase, dNTPs, MgCl2 and a special buffer sys-
tem with SGI dye. The final PCR reaction mix included 0.5
μmol/l of specific primer assay mixtures, 1 μl diluted
cDNA, DNase-free water and 2 μl QuantiTect SGI PCR
Master mix at a final volume of 10 μl. The cycle conditions
were set for PPIA, RPLPO and TUBB as follows: Taq DNA
polymerase activation at 95°C for 15 min with a ramping
rate of 20°C/s, start of each amplification cycle with a
denaturation step at 94°C for 15 s, primer annealing for
PPIA at 55°C for 20 s and for RPLPO and TUBB at 57°C
for 20 s, primer extension at 72°C for 20 s. The ramping
rate was 2°C/s for all 38 or 45 PCR cycles.
The target gene ADAM9  cDNA amplification was per-
formed with the ready-to-use LightCycler® FastStart DNA
MasterPLUS HybProbe (Roche). The final reaction concen-
trations of both primers were 0.5 μmol/l and the donor/
acceptor probe concentrations were 0.2 μmol/l each. The
PCR setup was: activation of FastStart Taq DNA Polymer-
ase at 95°C for 15 min, followed by 45 cycles of denatur-
ation at 95°C for 10 s, annealing at 62°C for 30 s and
elongation at 72°C for 30 s. The temperature transition
rate was 20°C/s. The final PCR volume of 20 μl included
1 μl of 1:5 diluted cDNA.
In dependence on gene-specific primer/probe sets for real-
time PCRs, the amplification rate detected as fluorescence
accumulation was gained by using probes after annealing
phase and by using SGI after elongation step. To evaluate
fluorescence data the method of Second Derivative Maxi-
mum of the LightCycler Software 3.5 (Roche) was uti-
lized. Crossing point (Cp) values as well as quantities
were applied for comparison of gene expressions in paired
samples. For the quantification of each gene a pooled
cDNA sample with a high expression value was stepwise
diluted and amplified. The undiluted sample was set as
one. The resulting standard curve was given in arbitrary
units. In each PCR run a diluted secondary standard was
used as calibrator and another cDNA dilution was used as
run-to-run precision control. Prior to this, the control
cDNA pool was adjusted in the range of sample expres-
sion level. In the same procedure the PCR efficiencies were
calculated (Table 2).
Each PCR run included a no template control with water
instead of cDNA. Duplicate measurements were per-
formed and mean values were used for all further calcula-
tions. To minimize the analytical variation paired
malignant and non-malignant samples were always ana-
lysed in the same PCR run.
Data analysis
Statistical analyses were performed with GraphPad Prism
for Windows, version 4.03 (GraphPad Software, San
Diego, CA, USA). The distribution fitting procedure
according to the D'Agostino & Pearson omnibus normal-
ity test was performed and non-parametric tests (Wil-
coxon test for paired samples; Mann-Whitney test) were
applied. Correlations were characterized by the Spear-
man's rank correlation coefficient rs. P < 0.05 values (two-
sided) were considered as statistically significant.
To characterize the expression stability of the candidate
reference genes, the programs geNorm, version 3.4 [4,28]
and NormFinder [29,30] were applied. geNorm processesBMC Molecular Biology 2007, 8:47 http://www.biomedcentral.com/1471-2199/8/47
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gene expression data as concentration values, taking into
account the PCR efficiencies of investigated genes (Table
2) [4]. The most stable genes are stepwise selected from
the investigated gene panel and a common Normalization
Factor (NF) can be calculated for the genes selected for the
normalization procedure.
The program NormFinder is a free Add-in for Microsoft
Excel [29,30]. NormFinder processes data in linear scale.
On the basis of a given "group identifier", the program
can discriminate between different groups, e.g. malignant
and non-malignant samples. The program algorithm
implies the estimation of intra- and intergroup variation
and combines both results in a stability value for each
investigated gene. The candidate gene with the lowest sta-
bility value is the most stable gene within the groups stud-
ied. The best combination of two genes is also indicated.
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